Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Ze-Long Liu†, Jing-Hua Liu†, Daniel Staiculescu and Jiang Chen

Abstract: Multikinase inhibitors (MKIs) have been the only first-line treatment for advanced hepatocellular carcinoma (HCC) for more than a decade, until the approval of immune checkpoint inhibitors (ICIs). Moreover, the combination regimen of atezolizumab (anti-programmed cell death protein ligand 1 antibody) plus bevacizumab (anti-vascular endothelial growth factor monoclonal antibody) has recently been demonstrated to have superior efficacy when compared with sorafenib monotherapy. The remarkable efficacy has made this combination therapy the new standard treatment for advanced HCC. In addition to MKIs, many other molecularly targeted therapies are under investigation, some of which have shown promising results. Therefore, in the era of immuno-oncology, there is a significant rationale for testing the combinations of molecularly targeted therapies and ICIs. Indeed, numerous preclinical and clinical studies have shown the synergic antitumor efficacy of such combinations. In this review, we aim to summarize the current knowledge on the combination of molecularly targeted therapies and immune checkpoint therapies for HCC from both preclinical and clinical perspectives.

Keywords: combination therapies, hepatocellular carcinoma, immune cells, immune checkpoint inhibitors, molecularly targeted therapies

Introduction
Liver cancer is one of the most common cancers and the fourth leading cause of cancer death globally, and its burden continues to rise steadily.1,2 Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 90% of all liver cancer cases.3 Molecularly targeted therapies, rather than chemotherapy, play crucial roles in the systematic therapy of unresectable HCC. The theory behind molecularly targeted therapies is that some molecular alterations function importantly during cancer development, growth, and metastasis, and may be potential targets for cancer treatment. For HCC, the most important molecular target is the vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Despite the extensive attempts at new drug development for HCC, sorafenib [multikinase inhibitor (MKI) of VEGFR] remained the sole, effective systemic therapy for nearly a decade (2007–2016) since its approval.4 In 2017, the situation changed due to the approval of regorafenib (MKI of VEGFR) as a second-line treatment for HCC patients who progressed on sorafenib treatment.5 Since then, numerous clinical trials on MKIs of VEGFR have yielded positive results, leading to the approval of lenvatinib6 as first-line treatment and cabozantinib7 and ramucirumab8 as subsequent-line treatments. In addition, there are many promising molecularly targeted agents currently being studied in clinical trials, such as transforming growth factor beta (TGF-β) inhibitors,9,10 MET inhibitors,11 fibroblast growth factor receptor 4...
Over the past decade, immune checkpoint blockade therapies targeting programmed cell death protein 1 (PD-1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) have made tremendous breakthroughs that have revolutionized the treatment of various cancers. Anti-PD-1 monotherapy has been approved for the treatment of advanced HCC in both first- and second-line settings based on clinical study data. However, in HCC, the overall response rate (ORR) to anti-PD-1 monotherapy was only 15–20% and, more importantly, the overall survival (OS) did not significantly improve. Given this data, researchers are currently making great efforts in improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) for HCC, including combining ICIs with other molecularly targeted therapies. Recently, on the basis of promising results of the IMbrave150 study, the combination of atezolizumab (anti-PD-L1 antibody) and bevacizumab (anti-VEGF monoclonal antibody) has been approved as a novel first-line treatment for advanced HCC. The final analysis of the clinical trial demonstrated that this combination resulted in significantly better OS and progression-free survival (PFS) than sorafenib monotherapy in patients with advanced HCC. This exciting result also suggests the promising future of combining molecularly targeted therapies and immune checkpoint blockade therapies in the treatment of advanced HCC.

Currently, there are an increasing number of studies evaluating various combination strategies of molecularly targeted therapies and immune checkpoint therapies for HCC. Although most combination strategies lack robust evidence at present, some have shown promising efficacy in animal models or clinical studies. In this review, we focus on the current knowledge of combining molecularly targeted therapies and immune checkpoint therapies in HCC and provide an outlook on the future of such combination therapies. For molecularly targeted therapies, we will mainly focus on VEGF/VEGFR inhibitors, TGF-β inhibitors, MET inhibitors, FGFR4 inhibitors, and epigenetic drugs, which have showed promising results in clinical studies (Figure 1; Table 1).
Table 1. Clinical trials testing various combinations of molecularly targeted therapies and ICIs in HCC.

| Trial identifier | Setting | Treatment | Phase | n  | Primary endpoints | Status     |
|------------------|---------|-----------|-------|----|-------------------|------------|
| **ICIs + VEGF/VEGFR inhibitors** |         |           |       |    |                   |            |
| NCT02715531      | Solid tumors; first line | Atezolizumab + bevacizumab | Ib    | 430 | PFS, ORR, safety  | Recruiting |
| NCT04180072      | Advanced HCC; first line | Atezolizumab + bevacizumab | II    | 48  | ORR               | Recruiting |
| NCT04563338      | Unresectable HCC and NSCLC with liver metastases; first or second line | Atezolizumab + bevacizumab | II    | 36  | PFS               | Recruiting |
| NCT03434379      | Advanced HCC; first line | Atezolizumab + bevacizumab versus sorafenib | III   | 480 | OS, PFS           | Completed  |
| NCT04487067      | Unresectable HCC; first line | Atezolizumab + bevacizumab | III   | 150 | Safety            | Recruiting |
| NCT04732286      | Unresectable HCC; first line | Atezolizumab + bevacizumab | III   | 100 | Safety            | Recruiting |
| NCT04393220      | Advanced HCC; first line | Nivolumab + bevacizumab | II    | 60  | OS, PFS           | Recruiting |
| NCT02519348      | Advanced HCC; first or second line | Durvalumab + bevacizumab | II    | 433 | Safety            | Recruiting |
| NCT04605796      | Advanced HCC; first line | Toripalimab + bevacizumab | II    | 60  | ORR, safety       | Recruiting |
| NCT04723004      | Advanced HCC; first line | Toripalimab + bevacizumab versus sorafenib | III   | 280 | OS, PFS           | Recruiting |
| NCT04741165      | Advanced HCC; first line | HX008 + bevacizumab/lenvatinib | II    | 72  | ORR               | Recruiting |
| NCT032111416     | Advanced HCC; first or second line | Pembrolizumab + sorafenib | I/II  | 27  | ORR               | Recruiting |
| NCT03439891      | Advanced HCC; first line | Nivolumab + sorafenib | II    | 40  | ORR, safety       | Recruiting |
| NCT02988440      | Advanced HCC; first line | PDR001 + sorafenib | Ib    | 20  | Safety            | Completed  |
| NCT04069494      | Unresectable HCC; first line | Toripalimab + sorafenib | I/II  | 39  | PFS, safety       | Recruiting |
| NCT04163237      | Advanced HCC; first line | PD-1 + sorafenib versus sorafenib | III   | 50  | DFS               | Recruiting |
| NCT04770896      | Unresectable HCC; second line | Atezolizumab + lenvatinib/sorafenib versus lenvatinib/sorafenib | III   | 554 | OS               | Recruiting |
| NCT03006926      | Advanced HCC; first line | Pembrolizumab + lenvatinib | Ib    | 104 | ORR, DOR, safety  | Recruiting |
| NCT04740307      | Advanced HCC; first line | Pembrolizumab/quivonlimab + lenvatinib | II    | 110 | ORR, safety       | Recruiting |
| NCT03713593      | Advanced HCC; first line | Pembrolizumab + lenvatinib versus lenvatinib | III   | 750 | OS, PFS           | Recruiting |
| NCT03418922      | Advanced HCC; first or second line | Nivolumab + lenvatinib | Ib    | 30  | Safety            | Recruiting |
| NCT03841201      | Advanced HCC; first line | Nivolumab + lenvatinib | II    | 50  | ORR, safety       | Recruiting |
| NCT04443309      | Advanced HCC; first line | SHR-1210 + lenvatinib | I/II  | 53  | ORR               | Recruiting |

(continued)
| Trial identifier | Setting                  | Treatment                                      | Phase | Primary endpoints | n   | Status     |
|-----------------|--------------------------|-----------------------------------------------|-------|------------------|-----|------------|
| NCT04542837     | Advanced HCC; first line | KN046 + lenvatinib                            | II    | ORR              | 30  | Recruiting |
| NCT04728321     | Advanced HCC; first line | AK104 + lenvatinib                            | III   | ORR              | 75  | Recruiting |
| NCT04484078     | Advanced HCC; first line | Tislelizumab + lenvatinib                     | IIb   | ORR, safety, PFS | 342 | Recruiting |
| NCT04728321     | Advanced HCC; first line | CS103 + lenvatinib versus lenvatinib          | III   | ORR, safety, PFS | 555 | Recruiting |
| NCT04423493     | Advanced HCC; first line | AK104 + lenvatinib                            | Ib    | ORR              | 66  | Recruiting |
| NCT04423493     | Advanced HCC; first line | Toripalimab + lenvatinib versus lenvatinib    | III   | ORR              | 466 | Recruiting |
| NCT04728321     | Advanced HCC; first line | Tislelizumab + lenvatinib                     | Ib    | ORR              | 76  | Recruiting |
| NCT04368078     | Advanced HCC; first line | Toripalimab + lenvatinib                      | Ib    | ORR              | 30  | Recruiting |
| NCT04728321     | Advanced HCC; first line | AK104 + lenvatinib                            | Ib    | Safety           | 60  | Recruiting |
| NCT04728321     | Advanced HCC; first line | CS103 + lenvatinib versus lenvatinib          | III   | Safety           | 42  | Recruiting |
| NCT04523493     | Advanced HCC; first line | AK104 + lenvatinib                            | Ib    | Safety           | 125 | Recruiting |
| NCT04523493     | Advanced HCC; first line | Toripalimab + lenvatinib versus lenvatinib    | III   | Safety           | 172 | Recruiting |
| NCT04728321     | Advanced HCC; first line | Tislelizumab + lenvatinib                     | Ib    | Safety           | 70  | Recruiting |
| NCT04728321     | Advanced HCC; first line | CS103 + lenvatinib versus lenvatinib          | III   | Safety           | 40  | Recruiting |
| NCT04194775     | Advanced HCC; first line | CS1003 + lenvatinib versus lenvatinib         | III   | Safety           | 525 | Recruiting |
| NCT03557911     | GI cancers; first or second line | Durvalumab + ramicucumab                     | Ib    | Safety           | 740 | Recruiting |
| NCT0430888      | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 29  | Recruiting |
| NCT04523493     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | III   | Safety           | 19  | Recruiting |
| NCT04523493     | Advanced HCC; first line | Pembrolizumab + cabozantinib                 | II    | Safety           | 154 | Recruiting |
| NCT04442581     | Advanced HCC; first line | Pembrolizumab + cabozantinib                 | II    | Safety           | 18  | Recruiting |
| NCT04283088     | Advanced HCC; first line | Pembrolizumab + cabozantinib                 | II    | Safety           | 114 | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 60  | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 190 | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 40  | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 30  | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 190 | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 40  | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 190 | Recruiting |
| NCT04542837     | Advanced HCC; first line | Pembrolizumab + regorafenib                  | II    | Safety           | 40  | Recruiting |

Table 1. (continued)
| Trial identifier   | Setting                              | Treatment                                         | Phase | n   | Primary endpoints | Status     |
|-------------------|--------------------------------------|---------------------------------------------------|-------|-----|-------------------|------------|
| NCT03764293       | Advanced HCC; first line             | SHR-1210 + apatinib versus sorafenib              | III   | 510 | OS, PFS           | Recruiting |
| NCT03852705       | Advanced biliary adenocarcinoma/HCC; first or second line | TQB2450 + anlotinib                              | Ib    | 60  | ORR               | Recruiting |
| NCT038512152      | Advanced HCC; first or second line   | Sintilimab + anlotinib                           | II    | 20  | ORR, safety       | Recruiting |
| NCT04172571       | Advanced HCC; first line             | AK 105 + anlotinib                               | Ib/Ib | 30  | ORR               | Recruiting |
| NCT04945158       | Advanced HCC; first line             | AK 105 + anlotinib versus sorafenib              | III   | 648 | OS                | Recruiting |
| NCT04612712       | Advanced GI cancers; first or second line | KN046 + donafenib                              | I/Ib  | 42  | ORR, safety       | Recruiting |
| NCT04503902       | Advanced HCC; first line             | Toripalimab + donafenib                          | I/Ib  | 46  | ORR, safety       | Recruiting |
| NCT04472858       | Advanced solid tumors; first or second line | CS1001 + donafenib                              | I/Ib  | 120 | ORR, safety       | Recruiting |
| NCT03970616       | Advanced HCC; first line             | Durvalumab + tivozanib                           | Ib/Ib | 42  | Safety            | Recruiting |
| NCT02856425       | Solid tumors; first or second line   | Pembrolizumab + nintedanib                       | Ib    | 18  | Safety            | Recruiting |
| NCT03941873       | Unresectable HCC or GC; first or second line | Tislelizumab + sitravatinib                     | I/Ib  | 104 | ORR, safety       | Recruiting |
| NCT04601610       | Advanced HCC; second line            | KN046 + ningetinib                               | Ib/Ib | 70  | ORR, safety       | Recruiting |
| NCT04560894       | Advanced HCC; first line             | SCT-110A + SCT510 versus sorafenib               | III   | 621 | OS, PFS           | Recruiting |
| NCT03973112       | Advanced HCC; second line            | HLX10 + HLX04                                    | II    | 150 | ORR               | Recruiting |
| NCT04465734       | Advanced HCC; first line             | HLX10 + HLX04 versus sorafenib                   | III   | 477 | OS, PFS           | Recruiting |
| NCT04072679       | Advanced HCC; second line            | Sintilimab + IBI305                              | Ib    | 50  | Safety            | Completed  |
| NCT03794440       | Advanced HCC; first line             | Sintilimab + IBI305 versus sorafenib            | II/III| 595 | OS, PFS           | Recruiting |
| **ICIs + TGF-β inhibitors** |                                       |                                                  |       |     |                   |            |
| NCT04429542       | Advanced solid tumors; first or second line | Pembrolizumab + BCA101                          | I     | 292 | Safety            | Recruiting |
| NCT02423343       | Solid tumors; second line            | Nivolumab + galunisertib                         | Ib/Ib | 75  | Safety            | Completed  |

**Table 1.** (continued)
### Table 1. (continued)

| Trial identifier | Treatment | Primary endpoints | Status | n | Setting | Phase |
|------------------|-----------|-------------------|--------|---|---------|-------|
| NCT03655613      | ICI + MET inhibitors | ORR, safety | Recruiting | 114 | Solid tumors; first or second line | I/II |
| NCT02947165      | PDR001 + NIS793 | ORR, safety | Recruiting | 60 | Solid tumors; first or second line | I |
| NCT02517398      | M7824 (PD-L1 and TGF-β inhibitors) | ORR, safety | Recruiting | 600 | Solid tumors; first or second line | I |
| NCT02699515      | M7824 (PD-L1 and TGF-β inhibitors) | Safety | Recruiting | 119 | Solid tumors; first or second line | I |
| NCT03257761      | Durvalumab + guadecitabine | DOR | Recruiting | 90 | Solid tumors; second line | Ib/II |
| NCT02325739      | PDR001 + capmatanib | Safety | Recruiting | 172 | Advanced HCC; second line | I/II |
| NCT04194801      | CS1001 + fisogatinib | ORR | Recruiting | 52 | Advanced HCC; first or second line | Ib/II |
| NCT02795429      | Nivolumab or APL-501 + APL-101 | ORR, safety | Recruiting | 90 | Solid tumors; first or second line | I |
| NCT02947165      | PDR001 + capmatanib | Safety | Recruiting | 114 | Solid tumors; first or second line | I |
| NCT02325739      | PDR001 + capmatanib | Safety | Recruiting | 172 | Advanced HCC; second line | I/II |
| NCT04194801      | CS1001 + fisogatinib | ORR | Recruiting | 52 | Advanced HCC; first or second line | Ib/II |
| NCT02947165      | PDR001 + capmatanib | Safety | Recruiting | 114 | Solid tumors; first or second line | I |
| NCT02325739      | PDR001 + capmatanib | Safety | Recruiting | 172 | Advanced HCC; second line | I/II |
| NCT04194801      | CS1001 + fisogatinib | ORR | Recruiting | 52 | Advanced HCC; first or second line | Ib/II |
| NCT02947165      | PDR001 + capmatanib | Safety | Recruiting | 114 | Solid tumors; first or second line | I |
| NCT02325739      | PDR001 + capmatanib | Safety | Recruiting | 172 | Advanced HCC; second line | I/II |
| NCT04194801      | CS1001 + fisogatinib | ORR | Recruiting | 52 | Advanced HCC; first or second line | Ib/II |

### Selection of clinical trials

To include clinical trials on the combination of molecularly targeted therapies and immune checkpoint therapies in HCC, we first searched the https://clinicaltrials.gov website by using the terms “hepatocellular carcinoma” and “drug.” A total of 1367 interventional trials were identified and further screened until February 2021. Trials were included only if they met the following criteria: (1) included patients with advanced or unresectable HCC; (2) included combination therapies of molecularly targeted therapies and immune checkpoint therapies; and (3) specific classes of molecularly targeted therapies, including VEGF/VEGFR inhibitors, TGF-β inhibitors, MET inhibitors, FGFR4 inhibitors, and epigenetic drugs. Studies were excluded if they met any of the following criteria: (1) combination therapies, such as neoadjuvant or adjuvant therapy; (2) combinations of molecularly targeted therapies and immune checkpoint therapies with other therapies; (3) have already been terminated or withdrawn; and (4) contained insufficient required information. The included clinical trials are summarized in Table 1.

### VEGF/VEGFR inhibitors

HCC is a hypervascularized solid tumor in which angiogenesis plays a critical role in cancer development, proliferation, and metastasis. VEGF/VEGFR inhibitors that modulate angiogenesis, including sorafenib, regorafenib, lenvatinib, cabozantinib, and ramucirumab, currently dominate the approved systemic therapies for advanced HCC. As for bevacizumab, a monoclonal anti-VEGF antibody with a long history, there is also some evidence, from clinical trials, indicating its potential efficacy in HCC. With the encouraging results of ICIs in HCC and the mounting evidence supporting the synergic effects of antiangiogenesis and immunotherapy, the potential of combining anti-VEGF/VEGFR drugs and ICIs in the treatment of advanced HCC has been investigated by plenty of animal and clinical studies.

In addition to promoting angiogenesis and increasing vessel permeability, the VEGF signaling pathway has also been found to play a crucial role in cancer immunity. In general, several mechanisms have been postulated for the immunosuppressive activity of the activation of the VEGF signaling pathway. Pathological angiogenesis generates abnormal vessels that may restrict...
the infiltration of immune cells into tumors.\textsuperscript{23} The upregulated level of VEGF could also result in the immunosuppressive tumor microenvironment (TME) by inhibiting the trafficking, proliferation, and effector function of cytotoxic T lymphocytes (CTLs) as well as the maturation and antigen presentation of dendritic cells (DCs). This, in turn, promotes immunosuppressive cell recruitment and proliferation, leading to a hypoxic and low-pH TME.\textsuperscript{23} Thus, inhibition of the VEGF–VEGFR interaction could not only normalize vasculature but also enhance antitumor immunity.\textsuperscript{20} The addition of ICIs could further prevent the immune evasion of tumors and has a potential synergic effect with VEGF/VEGFR inhibitors.\textsuperscript{20} Recently, Shigeta \textit{et al.} \textsuperscript{26} tested dual anti-PD-1/VEGFR-2 therapy in orthotopic murine models of HCC. They found that an anti-PD-1 antibody and an anti-VEGFR-2 antibody synergized in vessel normalization and immune microenvironment reprogramming, overcoming resistance to any of the individual treatments and thereby enhancing tumor elimination.\textsuperscript{26}

Recently released data from the IMbrave150 study demonstrated that atezolizumab plus bevacizumab resulted in higher ORR and prolonged OS and PFS when compared with sorafenib monotherapy.\textsuperscript{19} There are a number of clinical trials focusing on various combination regimens of VEGFR inhibitors and ICIs currently underway (Table 1). Here we will review these clinical studies and mainly focus on those with preliminary results.

**Bevacizumab**

After bevacizumab treatment, CD8\textsuperscript{+} T-cell proliferation is significantly increased while the presence of PD-L1+ tumor cells, PD-1+ cells, regulatory T (Treg) cells, and tumor-associated macrophages (TAMs) is significantly decreased in glioblastoma tissues.\textsuperscript{27} Bevacizumab could also increase CD8\textsuperscript{+} T-cell populations in tumor, reduce Treg cell populations in the blood, and sustain the circulation of the effector T cells.\textsuperscript{28–30} \textit{In vitro} and \textit{in vivo} administration of bevacizumab was shown to inhibit VEGF-mediated increases in Treg cells.\textsuperscript{31} Bevacizumab treatment resulted in a significant reduction of myeloid-derived suppressor cells (MDSCs), thereby restoring effective antitumor immunity.\textsuperscript{32–34} Previous studies also found that bevacizumab could abrogate the inhibition of monocytes differentiation into DCs.\textsuperscript{35–37} Bevacizumab was shown to enhance the maturation and number of DCs in the peripheral blood of patients with lung, breast, and colorectal cancers.\textsuperscript{38} Moreover, atezolizumab in combination with bevacizumab enhanced antigen-specific T-cell migration in metastatic renal cell carcinoma (RCC).\textsuperscript{39} Similarly, in patients with melanoma, a significant increases in circulating CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells occurred with ipilimumab plus bevacizumab \textit{versus} ipilimumab alone.\textsuperscript{40} To summarize, bevacizumab has significant effects on a variety of immune cells and contributes to the restoration of an immunosupportive TME.

These findings provide important rationales for the combination of bevacizumab and ICIs in cancer treatment. As previously mentioned, bevacizumab plus atezolizumab has recently become a new first-line treatment for advanced HCC (NCT03434379).\textsuperscript{19} Other clinical trials are also testing its efficacy (NCT02715531, NCT04180072, NCT04563338, NCT04487067, and NCT04732286).\textsuperscript{41} Other combinations of bevacizumab and ICIs, for instance, bevacizumab plus nivolumab (NCT04393220), bevacizumab plus durvalumab (NCT02519348), bevacizumab plus toripalimab (NCT04605796, NCT04723004), and bevacizumab plus HX-008 (NCT04741165) are also under investigation in clinical trials.

**Sorafenib**

Sorafenib can decrease suppressive immune cell populations, including Treg cells and MDSCs, and enhance functions of tumor-specific effector T cells.\textsuperscript{42–44} Sorafenib can also restore classical macrophage polarization in the TME of HCC, which correlates with a reduction in tumor burden.\textsuperscript{45,46} Sorafenib may also inhibit macrophage-induced hepatocarcinoma growth by acting on various targets.\textsuperscript{47,48} Similar to bevacizumab, sorafenib could abrogate the differentiation of human monocytes into DCs.\textsuperscript{35} In mouse models of various cancer types, sorafenib induced increased infiltration of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells into tumors.\textsuperscript{44,49–51} By contrast, in HCC mouse models or studies using peripheral blood mononuclear cells (PBMCs), the number and function of CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells may be depressed directly by sorafenib or indirectly by the elevation of MDSCs and Treg cells following sorafenib treatment.\textsuperscript{52,53} For natural killer (NK) cells, low-dose sorafenib may enhance NK cell effector functions, such as interferon gamma (IFN-\gamma)/tumor necrosis factor alpha (TNF-\alpha) production,
degranulation, and lytic functions,\textsuperscript{46,54} whereas high-dose sorafenib generally inhibits NK cell proliferation and function.\textsuperscript{55–58} On experimental models of HCC, sorafenib in combination with nivolumab showed a stronger tumor growth inhibition as opposed to sorafenib or nivolumab monotherapy.\textsuperscript{59}

Therefore, it is reasonable to test the combination of sorafenib and ICIs in clinical studies. Clinical trials of combined efficacy of sorafenib plus pembrolizumab (NCT03211416), nivolumab (NCT03439891), PDR001 (NCT02988440), toripalimab (NCT04069949), and atezolizumab (NCT04770896) are now ongoing.

**Lenvatinib**

In murine models of diverse cancers, lenvatinib monotherapy was found to increase the population of CD8\textsuperscript{+} T cells in TME and this effect was further enhanced when combined with an anti-PD-1 antibody.\textsuperscript{60–62} Lenvatinib enhanced the antitumor activity of PD-1 blockade by upregulating memory T-cell population and enhanced T helper type 1 (Th1) immune response.\textsuperscript{63,64} It was also found that the antitumor activity of lenvatinib was associated with enhanced tumor immune infiltration and activation of NK cells in HCC models.\textsuperscript{65} More importantly, lenvatinib may decrease TAMs in RCC, colon cancer, and thyroid cancer tumor models, and exhibited synergistic antitumor effects in combination with anti-PD1 therapy.\textsuperscript{64,66–68}

In a phase Ib clinical trial (NCT03006926), lenvatinib plus pembrolizumab was assessed as a first-line treatment in advanced HCC.\textsuperscript{69} The combination therapy showed promising antitumor activity with an ORR of 36.0\% [95\% confidence interval (CI): 26.6–46.2\%] and a tolerable safety profile.\textsuperscript{69} Another phase Ib clinical trial of lenvatinib plus nivolumab, in patients with unresectable HCC, reported an ORR as high as 76.7\% (95\% CI: 57.7–90.1\%) and manageable adverse events (NCT03418909).\textsuperscript{70} A phase II trial of lenvatinib plus nivolumab in HCC is currently underway (NCT03841201).\textsuperscript{71} A phase III trial aiming to compare the efficacy of the combination of lenvatinib and pembrolizumab with lenvatinib monotherapy, as first-line treatment for HCC, is also now underway (NCT03713593).\textsuperscript{72} Other clinical trials on the combination of lenvatinib and ICIs are listed in Table 1.

**Regorafenib**

Regorafenib was previously reported to decrease macrophage accumulation in several murine models of colorectal cancer.\textsuperscript{73,74} When administered in mice, regorafenib suppressed melanoma progression in a CD8\textsuperscript{+} T-cell-dependent manner.\textsuperscript{75} Recently, regorafenib was found to promote tumor immunity by targeting the RET–Src axis to further inhibit JAK1/2–STAT1 and MAPK signaling as well as attenuate IFN-γ-induced PD-L1 and indoleamine 2,3-dioxygenase 1 (IDO1) expression.\textsuperscript{76}

For HCC, early stage clinical trials of regorafenib plus avelumab (NCT03475953), pembrolizumab (NCT03347292, NCT04696055), nivolumab (NCT04170556, NCT04310709), sintilimab (NCT04718909), and tislelizumab (NCT04183088) are ongoing at present.

**Cabozantinib**

Cabozantinib rendered tumor cells more sensitive to immune-mediated killing and contributed to a more permissive immune environment in experimental study.\textsuperscript{77} Cabozantinib treatment also resulted in a significant reduction of MDSCs in mouse models.\textsuperscript{34} In clinical trials, cancer patients treated with cabozantinib were found to have increased CD8\textsuperscript{+} T cells and decreased Treg cells and MDSCs.\textsuperscript{78,79} Furthermore, cabozantinib was reported to trigger a neutrophil-mediated anticancer innate immune response that resulted in tumor clearance.\textsuperscript{80} Cabozantinib could downregulate M1 macrophages to prevent bone metastasis of prostate carcinoma\textsuperscript{81} and reverse c-MET-induced immunosuppressive PD-L1 upregulation.\textsuperscript{82}

In one cohort from the CheckMate 040 study, the triple combination of nivolumab, ipilimumab, and cabozantinib led to an ORR of 26\% with tolerable toxicity.\textsuperscript{83} There are also ongoing clinical trials testing cabozantinib plus pembrolizumab (NCT04442581), nivolumab (NCT04514484), atezolizumab (NCT03170960, NCT03755791), and durvalumab (NCT03539822) for HCC patients.

**Ramucirumab**

Ramucirumab-containing therapies for gastric cancer (GC) patients displayed significantly increased CD8\textsuperscript{+} T-cell infiltration, decreased
Treg cell infiltration, and reduced PD-1 expression by CD8+ T cells.84

A phase Ib study (NCT02572687) showed that ramucirumab plus durvalumab yielded increased antitumor activity without unexpected toxicity in HCC patients, especially those with high PD-L1 expression.85

Others

SHR-1210 (anti-PD-1 antibody) and apatinib combination therapy demonstrated an ORR of 50.0% (95% CI: 24.7–75.4%) in advanced HCC patients (NCT02942329).86 A phase Ib trial (NCT03289533) evaluating avelumab plus axitinib in treatment-naïve patients with HCC showed an ORR of 31.8% (95% CI: 13.9–54.9%).87

As shown in Table 1, many other combinations of anti-VEGF/VEGFR antibodies and ICIs are now under investigation in clinical trials.

**TGF-β inhibitors**

The TGF-β pathway has miscellaneous functions in cancers, including regulating cell growth, differentiation, apoptosis, motility and invasion, extracellular matrix production, angiogenesis, and immune response.88,89 In HCC, TGF-β signaling has been demonstrated to be significant in a subset of patients based on gene expression profiling.90 It is found that TGF-β1, an isoform of TGF-β, can stimulate α3-integrin expression in noninvasive HCC cells at the transcriptional level, transforming them into a motile and invasive phenotype.91 In an experimental model of hepatocyte transmigration using hepatic sinusoidal endothelial cells and malignant hepatocytes to mimic vascular invasion, TGF-β was shown to be crucially involved in blood vessel invasion of HCC cells. This suggests its key role in the dissemination and metastasis of HCC.92 In addition, TGF-β was found to contribute to HCC invasion and metastasis by inducing FGFR4 expression through the extracellular-signal-regulated kinase (ERK) pathway.93 TGF-β signaling also functions as a master regulator for immune cell proliferation, differentiation, development, and survival.94,95 In the liver, TGF-β signaling plays a crucial role in regulating immune cells to maintain a balance between immune tolerance and activation96–98 (Figure 2). TGF-β activity has been identified as essential for the pathogenesis of HCC, including the activation of cancer-associated fibroblasts (CAFs).96–98

The potent immunosuppressive function of Treg cells is a major hurdle in generating an effective antitumor response in HCC.99 Tumor cells and all stromal cells, including MDSCs, TAMs, DCs, CAFs, hepatic stellate cells (HSCs), and liver sinusoidal endothelial cells (LSECs) modulate Treg cell activity in HCC via the TGF-β pathway. MDSCs play a critical role in tumor-induced liver immunosuppression by inhibiting NK cell functions through membrane-bound TGF-β and promoting Treg cell expansion.100,101 TGF-β, in the TME, promotes the expression of T-cell immunoglobulin mucin receptor 3 (TIM3) on macrophages and facilitates the alternative activation of macrophages via TIM3, thereby promoting tumor growth via the nuclear factor-κB (NF-κB)-interleukin 6 (IL-6) axis.102 TGF-β promotes the differentiation of M2 macrophages, which repress CD8+ T-cell, NK cell, and DC functions and increase Treg cell functions.103 A subset of DCs selectively promote the proliferation of Treg cells in a TGF-β dependent manner.104 TGF-β expressed and activated by cancer cells, or other cells in the TME, promote cancer progression through its effects on CAFs.105 CAFs are important components of the HCC TME, generating cyclooxygenase-2 (COX2), IL-8, and other cytokines that, together, stimulate TAMs to release TNF-α and platelet-derived growth factor (PDGF).96–98 HSCs are activated by TGF-β and induce immune tolerance via enhancing the expansion of MDSCs, attenuation of effector T-cell functions, and augmentation of Treg cells.106,107 LSECs are the most efficient liver cell type in TGF-β-dependent Treg cell induction and produce the chemokine C-X-C motif chemokine ligand 16 (CXCL16) to control the accumulation of C-X-C motif chemokine receptor 6 (CXCR6) + NKT cells.108,109

TGF-β has been demonstrated to induce forkhead box P3 (Foxp3), a transcriptional factor expressed predominantly on Treg cells, through a Smad2/3-dependent mechanism.110 Foxp3+ Treg cells are highly enriched in tumors of HCC patients and correspond to poorer clinical outcomes.111 Treg cells also secrete TGF-β, as well as adenosine and IL-10, to suppress effector T cells, such as CD8+ CTLs,112 which play a critical role in the antitumor immune response by the production of various effector molecules including IFN-γ, IL-2, and TNF-α.113 CD28 is a
co-stimulatory molecule that interacts with the CD80/CD86 complex on antigen-presenting cells (APCs). The immune checkpoint molecule expressed on Treg cells, CTLA4, can compete with CD28 to downregulate the CD80/CD86 complex through CTLA-4-mediated trans-endocytosis, thus inhibiting the antitumor immunity.114,115 TGF-β has also been implicated in inducing Treg cell polarization.116 Accordingly, inhibition of the TGF-β signaling decreased Treg cell infiltration in tumor tissues and induced HCC tumor regression.116 Therefore, targeting Treg cells, such as by blocking the TGF-β signaling or the membrane-bound receptor CTLA-4, may be a particularly effective immune-based approach for improving the immune response against HCC.

IFN-γ is a cytokine that supports the proliferation and differentiation of myeloid cells and CD8+ T cells. In numerous immune cell types, TGF-β suppresses IFN-γ expression via the Smad pathway, thereby inhibiting the antitumor activity of CD8+ T cells.117,118 Th1 and Th2 lineages produce cytokines that support the growth and functions of CD8+ cytotoxic T cells, B cells, and macrophages. TGF-β restricts the specification of Th1 and Th2 cells by repressing T-bet expression and inducing MSC and Sox4 expression, respectively.118 Additionally, TGF-β was demonstrated to promote a shift of Th1 toward Th2 cell differentiation, resulting in a less efficient antitumor immune response.119 Th17 cells are a proinflammatory Th cell subtype that expresses IL-17 and contribute to non-alcoholic steatohepatitis (NASH) and HCC.120,121 Through the activation of Smad2/3, TGF-β cooperates with IL-6/IL-21 to positively regulate the generation of Th17 cells from naive CD4+ T cells.120,121 Intratumoral TGF-β suppresses NKT cells, which are responsible for recruiting effector immune cells to the tumor by producing large amounts of IFN-γ.122 NKG2D is one of the NK cell activating receptors. Active NKG2D can induce the activation, cytokine production, degranulation, and cytotoxic potential in NK cells.123 Downregulation of NKG2D or upregulation of the inhibitory receptor NKG2A is associated with increased generation of immunosuppressive cytokines, such as TGF-β and IL-10, contributing to NK cell dysfunction in HCC.124–129 Although TGF-β promotes chemotaxis of eosinophils and mast cells, it inhibits effector functions of NK cells and antigen presentation by DCs.95,130 During B-cell maturation, TGF-β stimulates class switch recombination, which converts IgM-expressing B cells into IgA-expressing (IgA+) cells with regulatory activity.131 IgA+ cells are involved in nonalcoholic fatty liver disease (NAFLD)-associated HCC by co-expressing PD-L1 and IL-10 and by restraining cytotoxic CD8+ T lymphocytes.132

**Figure 2.** Interactions between TGF-β and immune cells in the tumor microenvironment of hepatocellular carcinoma.
TGF-β enhances antigen-induced PD-1 expression on tumor-infiltrating lymphocytes (TILs) through Smad3-dependent transcriptional activation. And TGF-β induced epithelial–mesenchymal transition (EMT) increases PD-L1 expression in tumor cells. The engagement of the co-inhibitory receptor PD-1 or its ligand PD-L1 blocks T-cell antigen receptor (TCR) signaling and inhibits T-cell proliferation and secretion of cytotoxic mediators, including granzyme A (GZMA), granzyme B (GZMB), TNF-α, and IFN-γ, which all collectively lead to T-cell exhaustion. Thus, increased TGF-β signaling may allow tumors to evade host immune responses by upregulating PD-1 expression, and inhibition of TGF-β signaling may directly enhance antitumor immunity. Tumors, particularly immune-excluded tumors that are intrinsically resistant to anti-PD-1/PD-L1 therapy, display elevated TGF-β signaling. Indeed, anti-PD-1 treatment can induce a competing TGF-β-driven immunosuppressive program in a mouse model. Together, these findings provide an important rationale for blocking the TGF-β signaling in order to circumvent the aggressiveness and resistance to therapies of HCC, especially in the era of immune-oncology.

Pharmacological agents targeting the TGF-β pathway, including receptor kinase inhibitors and neutralizing antibodies that inhibit the interactions of TGF-β ligands with their receptors, have already demonstrated promising antitumor efficacy in early clinical trials with an acceptable safety profile in a variety of cancers, including HCC. Dual blockade of TGF-β signaling and PD-1/PD-L1 checkpoint successfully reduced TGF-β signaling in stromal cells, promoted T-cell infiltration into tumor centers, elicited vigorous antitumor immunity, and contributed to tumor regression in mouse models. In addition, M7824, a bifunctional fusion protein consisting of an α-PD-L1 antibody moiety, based on avelumab linked to the extracellular domain of TGF-β receptor II, was developed. This novel agent blocked signaling from the immune checkpoint PD-L1 surface protein and reduced TGF-β signaling within the TME by binding to all three TGF-β isoforms. Its dual anti-immunosuppressive function led to the activation of the innate and adaptive immune systems, upregulation of PD-L1 levels in tumor cells, and induction of tumor regression in mouse models. Another bifunctional fusion protein that blocks both TGF-β and CTLA-4 has also been developed, which was more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody. Early clinical trials of M7824 in patients with metastatic or locally advanced solid tumors, including HCC, have shown encouraging efficacy and a manageable safety profile (NCT02517398, NCT02699515) (Table 1). A clinical trial of galunisertib (a systemic TGF-β receptor 1 inhibitor) in combination with nivolumab for HCC is ongoing (NCT02423343) (Table 1). Other clinical trials testing BCA101 (EGFR/TGF-β fusion monoclonal antibody) plus pembrolizumab (NCT04429542) or NIS793 (TGF-β inhibitor) plus PDR001 (spartalizumab, PD-1 inhibitor) (NCT02947165) are also ongoing (Table 1).

**MET inhibitors**

c-MET (MET) is a tyrosine kinase receptor with a single known ligand, hepatocyte growth factor (HGF). In HCC, overexpression of c-MET and HGF was noted in 20% and 33% of human samples, respectively. The MET/HGF axis is involved in HCC progression by promoting cellular proliferation, survival, and invasion. The MET/HGF signaling pathway is also associated with tyrosine kinase inhibitor resistance, as patients with plasma HGF concentrations above 3279.1 pg/ml derived no obvious benefit from sorafenib compared with placebo in the pivotal phase III SHARP trial. Therefore, the MET/HGF pathway may be used as a potential therapeutic target for the treatment of HCC. Moreover, the MET/HGF pathway has complex immunomodulatory effects (Figure 3). It can act as an immunosuppressive stimulus by negatively affecting DCs and T lymphocytes, or as an immune-positive stimulus by promoting the recruitment of DCs, B cells, and T lymphocytes.

To date, the potential interplay between the HGF/MET pathway and DCs has been extensively investigated. It is well known that DCs are involved in the presentation of tumor-associated antigens (TAAs) and the activation of CD4+ T cells, but the role of DCs in regulating T-cell activity has not been thoroughly studied. Several studies have found that HGF is able to enhance this function and plays a positive role in the immune response. However, it has also been shown that HGF can act as a potent negative regulator of DC function and can induce an increase of Treg cells, a decrease of IL-17-producing T cells, and an increase in...
IL-10 and TGF-β, which are known for their immunosuppressive effects.\textsuperscript{157} The inhibition of DC functions, together with the decrease of CD8\textsuperscript{+} T cells and the increase of Treg cells, leads to a decline of anticancer immunity.\textsuperscript{156} Moreover, HGF favors the differentiation of monocytes into IL-10\textsuperscript{+} regulatory DCs. This inhibitory effect has also been demonstrated in monocytes, particularly with an induction toward differentiation into IL-10\textsuperscript{+} regulatory DCs.\textsuperscript{165}

Besides APCs, the impact of HGF/MET signaling on granulocytes has also been highlighted in previous studies. MET is required for neutrophil chemoattraction and cytotoxicity, while its deletion in mouse neutrophils enhances tumor growth and metastasis.\textsuperscript{166} This phenotype is associated with reduced neutrophil infiltration to both primary and metastatic tumors in clinical samples.\textsuperscript{166} Mechanistically, tumor-derived TNF-α or other inflammatory stimuli can induce MET in neutrophils, which results in neutrophil transmigration across an activated endothelium and inducible nitric oxide synthase production, thereby promoting cancer cell killing and abating tumor progression.\textsuperscript{166} This mechanism may partially explain the resistance to MET inhibitors in some patients, which is an important issue for clinicians in developing treatment strategies.\textsuperscript{166} This example reveals the complex role of MET in tumors regarding its immunomodulatory effects, which is of great importance when testing its combination with immunotherapy. In HCC, tumor neutrophils actively enhanced the metastasis of malignant cells \textit{in vitro} and \textit{in vivo} via HGF/c-MET interaction.\textsuperscript{167}

c-MET inhibition promoted perforin expression in CD8\textsuperscript{+} T cells and contributes to the activation of the immune system.\textsuperscript{168} c-MET inhibition impaired the reactive mobilization and recruitment of neutrophils into tumors and draining lymph nodes, potentiating T-cell antitumor immunity.\textsuperscript{169} Furthermore, in immunocompetent mice, the addition of MET inhibitors to immunotherapy increased the number of active T cells and changed their phenotype by reducing the proportion of exhausted T cells.\textsuperscript{169} These results were independent of MET expression in the tumor models used, suggesting that c-MET inhibitor co-treatment may improve the response to cancer immunotherapy in settings beyond c-MET-dependent tumors.\textsuperscript{169}

MET was identified as a broadly expressed TAA that can be recognized by CD8\textsuperscript{+} cytotoxic T cells, which then triggered activation of the immune system against cancer cells overexpressing MET.\textsuperscript{170} Similarly, Kumai \textit{et al.}\textsuperscript{171} showed that MET expression itself behaves as a TAA, which was able to activate CD4\textsuperscript{+} T cells and to induce tumor cell killing in NKT-cell lymphoma (NKTCL) cell lines. Particularly, in this model, MET elicited a specific antitumor immune response with three newly identified MET-induced T-cell epitopes. The activation of T cells was stronger in the presence of MET inhibitors since it caused a reduction of the synthesis of
TGF-β from tumor cells. Additionally, the presentation of MET-derived peptides by major histocompatibility complex class II (MHCII) to CD4+ T cells was influenced by chaperon processing and autophagy, thus proposing an innovative potential role of autophagy inducers as immune activators. Finally, since HGF/MET stimulation increases the proliferation of NKTCL cells in vitro, MET inhibition again displayed a dual role: direct tumor killing for MET-dependent cell survival and anti-tumor immune activation.171

PDL-1/2 expression was found to correlate significantly with c-MET expression in GC patients.172 c-MET was shown to upregulate PD-L1 expression, contributing to immune escape of tumor cells in various cancers including GC, non small cell lung cancer (NSCLC), RCC, and HCC.82,173–179 However, there are also some preclinical studies showing the opposite effect of c-MET in terms of the regulation of PD-L1 expression. MET-mediated phosphorylation and activated glycogen synthase kinase 3β (GSK3β) can lead to decreased expression of PD-L1.180 Exposure of liver cancer cell lines to MET inhibitors increased their expression of PD-L1 and inactivated co-cultured T cells.180 In combination with a MET inhibitor, anti-PD-1 and anti-PD-L1 produced additive effects to slow the growth of HCCs in mice.180 Similarly, exposure of NSCLC cell lines to the c-MET inhibitor, tivantinib, increased their PD-L1 expression, which in turn caused cells to become more resistant to T-cell killing. This provides a rationale for the use of the combination therapy of c-MET inhibitors and ICIs in NSCLC.181 Moreover, a novel bispecific antibody targeting both MET and PD-L1 was developed and studied in multiple cancer cell-type models.182,183 The antibody exhibited strong anti-proliferative and anti-metastatic effects in vitro and in vivo and reduced the production of inflammatory chemokines such as IL-6 and TNF-α, thus suggesting an important therapeutic potential, although it is still in the preclinical model stage.182,183 Besides, clinical trial of APL-101 (c-MET inhibitor) plus nivolumab or APL-501 (PD-1 inhibitor) (NCT03655613) and capmatanib (MET inhibitor) plus PDR001 (NCT02795429) are recruiting patients (Table 1).

**FGFR4 inhibitors**

FGFR4 is the predominant FGFR expressed in the liver and has been identified as a promising target in HCC.184 Fibroblast growth factor 19 (FGF19) can bind to and activate FGFR4 to induce hepatocyte proliferation.185 The activation of the FGF19/FGFR4 pathway suppresses E-cadherin expression and hence promotes EMT, contributing to the aggressiveness of HCC.186 FGF19 was significantly overexpressed in HCC specimens and was independently associated with tumor progression and poor prognosis in HCC patients.187,188 Additionally, FGF19 was found to be strongly associated with the immune checkpoint signature (CD274, PDCD1, BTLA, CTLA4, HAVCR2, IDO1, and LAG3) in lymphoepithelioma-like HCC (LEL-HCC).189 As previously described, FGFR4 expression was upregulated by TGF-β through the ERK pathway, in HCC cell lines, which contributed to the metastatic dissemination of HCC in vivo.93 More importantly, FGF19/FGF4 signaling plays an important role in the resistance of HCC to sorafenib,190,191 making it of particular interest given the current widespread use of MKIs in HCC patients. A clinical trial testing FGF401 (FGFR4 inhibitor) plus PDR001 (NCT02325739), and another clinical trial testing fisogatinib (FGFR4 inhibitor) plus CS1001 (PD-1 inhibitor) (NCT04194801), in HCC, are both currently ongoing (Table 1).

**Epigenetic drugs**

Epigenetic events play a crucial role in tumor development, progression, and metastasis, providing another potential target for cancer treatment.192–194 Owing to their effect on immune response and cancer immunity,195 there are strong rationales for the potential combination of epigenetic drugs and ICIs in cancers. Epigenetic modifiers function importantly in priming and enhancing the therapeutic effect of the host immune system against cancer.196,197 PBMCs and T-cell DNA methylation in HCC suggested that a broad molecular signature was involved in tumor progression, which was highly enriched in immune function-related genes such as PD-1.198 Another study also found that highly upregulated DNA methyltransferases (DNMTs) were positively correlated with PD-L1 overexpression in sorafenib-resistant HCC cells.199 Knockdown of PD-L1 induced DNMT1-dependent DNA hypomethylation and restored the expression of methylation-silenced Cadherin 1, a metastasis suppressor in HCC.199 Epigenetic drugs, such as DNMT inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi), were found to upregulate the expression of inhibitory immune checkpoints in either
immune or cancer cells, which enhance the response to immune checkpoint therapy.\textsuperscript{196,197,200–207} DNMTi enhanced the therapeutic efficacy of PD-L1 blockade and increased tumor-infiltrating CD8\textsuperscript{+} T cells and Th1-type chemokine expression in ovarian cancer in C57/BL6 mice.\textsuperscript{106} In a mouse model of fibrosis-associated HCC, the combination of i-BET762 (BET inhibitor) and anti-PD-L1 therapy was found to be able to repress monocytic MDSCs, enhance TILs, and lead to tumor eradication and prolonged survival.\textsuperscript{208} The therapeutic effect of a HDACi belinostat in combination with immune checkpoint blockades (ICBs) was highlighted in a murine model of HCC, which was associated with enhanced IFN-\gamma production by antitumor T cells and a decrease in Treg cells.\textsuperscript{209} Hong et al.\textsuperscript{210} demonstrated that epigenetic therapy targeting EZH2 and DNMT1 could be a potential strategy to augment immunotherapy for HCC by stimulating T-cell trafficking into the TME. Guadecitabine, a second-generation DNMTi, showed synergistic antitumor effects with immune checkpoint therapy and provided a rationale for such combination treatment.\textsuperscript{211} As a result, a clinical trial of durvalumab plus guadecitabine (NCT03257761) for HCC patients is currently ongoing (Table 1).

Others
A phase I study (NCT02476123) of the anti-CCR4 antibody mogamulizumab in combination with nivolumab in patients with advanced or metastatic solid tumors, including HCC, demonstrated acceptable antitumor activity and safety profile.\textsuperscript{212} There are now also a lot of combination therapies of other molecular targeted therapies and immune checkpoint therapies for HCC under investigation, such as pembrolizumab plus bavotuximab (NCT03519997), nivolumab plus SF1126 [phosphatidylinositol 3-kinase (PI3K) inhibitor] (NCT03059147), nivolumab plus copanlisib (PI3K inhibitor) (NCT03735628), nivolumab plus abemaciclib [cyclin-dependent kinase 4 (CDK4) inhibitor] (NCT03781960), nivolumab plus cabiralizumab [colony-stimulating factor 1 receptor (CSF1R) antagonist] (NCT04050462), nivolumab plus BMS-986253 (IL-8 inhibitor) (NCT04050462, NCT04123379), pembrolizumab/nivolumab/atezolizumab/avelumab plus ALT-803 [IL-15 receptor (IL-15R) agonist] (NCT03228667), nivolumab plus BMS-813160 (CCR2 antagonist) (NCT04123379), nivolumab plus CC-122 (NCT02859324), etc.

Conclusion
Plenty of novel agents are under development and investigation in the post-sorafenib era of advanced HCC treatment. Among them, molecular targeted drugs and ICIs are by far the most promising. Various combination strategies of molecular targeted therapies and immune checkpoint therapies are being tested and have generated some encouraging preliminary data. We are continuing to experiment with various therapeutic approaches to improve the clinical outcome of advanced HCC. One of the biggest challenges in order to optimize treatment outcomes is the development of predictive biomarkers for both monotherapies and combination therapies to accurately identify patients most likely to respond to particular treatments. In HCC, MKIs have been used for more than a decade and ICIs have been approved for several years, yet there are still no satisfactory biomarkers for these two therapies. For combination therapies, a better understanding of the mechanisms of synergistic therapeutic effects would aid in the design of more effective treatment regimens, such as dosing and sequencing strategies. Finally, the prevention and management of toxicities of combination therapies should be taken seriously in clinical practice.

Acknowledgements
We thank the patients and investigators who participated in clinical trials for providing data.

Author contributions
Conceptualization, ZLL, and JC; Methodology, ZLL, and JHL; Software, ZLL; Formal Analysis, ZLL and JHL; Investigation, ZLL; Writing – Original Draft Preparation, ZLL and JC; Writing – Review and Editing, JC and DS; Supervision, JC. All authors have read and agreed to the published version of the manuscript.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported...
by the Basic and Applied Basic Research Fund of Guangdong Province, China (grant number: 2020A1515110491), the Fundamental Research Funds for the Central Universities (grant number: K20200089), the National Natural Science Foundation of China (grant number: 81702981), the China Postdoctoral Science Foundation Funded Project (grant number: 2020T130584), Zhejiang Provincial Natural Science Foundation of China (grant number:LY20H160021) and the China Scholarship Council (grant number: 201806325017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
2. Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol 2017; 3: 1683–1691.
3. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 2: 16018.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
5. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56–66.
6. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391: 1163–1173.
7. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379: 54–63.
8. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282–296.
9. Ikeda M, Morimoto M, Tajimi M, et al. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Invest New Drugs 2019; 37: 118–126.
10. Giannelli G, Santoro A, Kelley RK, et al. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS One 2020; 15: e0222259.
11. Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology 2018; 67: 1132–1149.
12. Kim RD, Sarker D, Meyer T, et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGFR1 signaling as a driver event in hepatocellular carcinoma. Cancer Discov 2019; 9: 1696–1707.
13. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389: 2492–2502.
14. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940–952.
15. Kudo M, Matilla A, Santoro A, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. J Clin Oncol 2019; 37: 327.
16. Kambhampati S, Bauer KE, Bracci PM, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer 2019; 125: 3234–3241.
17. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020; 38: 193–202.
18. Sangro B, Park J, Finn R, et al. LBA-3 CheckMate 459: long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients
with advanced hepatocellular carcinoma. Ann Oncol 2020; 31: S241–S242.

19. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894–1905.

20. Hato T, Zhu AX and Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 2016; 8: 299–313.

21. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992–2998.

22. Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012; 17: 1063–1072.

23. Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 2018; 15: 325–340.

24. Georganaki M, van Hooren L and Dimberg A. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol 2018; 9: 3081.

25. Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and antiangiogenesis in cancer treatment. Mol Cancer 2019; 18: 60.

26. Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 2020; 71: 1247–1261.

27. Tamura R, Tanaka T, Ohara K, et al. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. Cancer Sci 2019; 110: 499–508.

28. Napoletano C, Ruscito I, Bellati F, et al. Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets. J Clin Med 2019; 8: 380.

29. Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73: 539–549.

30. Mansfield AS, Nevala WK, Lieser EA, et al. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013; 2: e24436.

31. Wada J, Suzuki H, Fuchino R, et al. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 2009; 29: 881–888.

32. Feng PH, Chen KY, Huang YC, et al. Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 2018; 13: 958–967.

33. Kusmartsev S, Eruslanov E, Kübler H, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008; 181: 346–353.

34. Lu X, Horner JW, Paul E, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017; 543: 728–732.

35. Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100: 1111–1119.

36. Michielsens AJ, Noonan S, Martin P, et al. Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment. Mol Cancer Ther 2012; 11: 1829–1837.

37. Michielsens AJ, Ryan EJ and O’Sullivan JN. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 2012; 1: 1445–1447.

38. Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57: 1115–1124.

39. Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016; 7: 12624.

40. Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2: 632–642.

41. Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol 2020; 21: 808–820.
42. Cao M, Xu Y, Youn J-I, et al. Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest 2011; 91: 598–608.

43. Chen ML, Yan BS, Lu WC, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer 2014; 134: 319–331.

44. Chuang HY, Chang YF, Liu RS, et al. Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment. PLoS One 2014; 9: e109992.

45. Heindryckx F, Coulon S, Terrie E, et al. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. J Hepatol 2013; 58: 319–328.

46. Sprinzl MF, Reisinger F, Puschnik A, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57: 2358–2368.

47. Wei X, Tang C, Lu X, et al. MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Oncotarget 2015; 6: 18389–18405.

48. Sprinzl MF, Puschnik A, Schlitter AM, et al. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J Hepatol 2015; 62: 863–870.

49. Mathew NR, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 2018; 24: 282–291.

50. Romero AI, Chaput N, Poirier-Colame V, et al. Regulation of CD4+ NKG2D+ Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15α and NKG2D triggering. Cancer Res 2014; 74: 68–80.

51. Sunay MM, Foote JB, Leatherman JM, et al. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol 2017; 46: 112–123.

52. Chang C-J, Yang Y-H, Chiu C-J, et al. Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. Int J Cancer 2018; 142: 1878–1889.

53. Zhao W, Gu YH, Song R, et al. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008; 22: 1226–1233.

54. Lohmeyer J, Nerreter T, Dotterweich J, et al. Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner. Clin Exp Immunol 2018; 193: 64–72.

55. Martin del Campo SE, Levine KM, Mundy-Bosse BL, et al. The Raf kinase inhibitor sorafenib inhibits JAK-STAT signal transduction in human immune cells. J Immunol 2015; 195: 1995–2005.

56. Stehle F, Schulz K, Fahldieck C, et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 2013; 288: 16334–16347.

57. Zhang QB, Sun HC, Zhang KZ, et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS One 2013; 8: e55945.

58. Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009; 183: 8286–8294.

59. Wang Y, Li H, Liang Q, et al. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. Tumour Biol 2015; 36: 1561–1566.

60. Gunda V, Gigliotti B, Asghy T, et al. Anti-PD-1/ PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer 2019; 144: 2266–2278.

61. Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 2019; 14: e0212513.

62. Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci 2018; 109: 3993–4002.

63. Kato Y, Bao X, Macgrath S, et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Jpn Soc Med Oncol 2016; 27: 1–14.
1. Llovet JM, Kudo M, Cheng A-L, et al. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model. Cancer Sci 2013; 104: 201–207.

2. Makker V, Cohn A, Taylor M, et al. Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma. J Clin Oncol 2018; 36: 5597.

3. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020; 38: 2960–2970.

4. Kudo M, Ikeda M, Motomura K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. J Clin Oncol 2020; 38: 513.

5. Mueller D, Siegler G, Toni E, et al. Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): an open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/ L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). J Clin Oncol 2020; 38: e16601.

6. Llovet JM, Kudo M, Cheng A-L, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J Clin Oncol 2019; 37: TPS4152.

7. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 2013; 12: 1322–1331.

8. Hoff S, Grünewald S, Röse L, et al. 1198PLimmunomodulation by regorafenib alone and in combination with anti PD1 antibody on murine models of colorectal cancer. Ann Oncol 2017; 28(Suppl. 5): 423.

9. Tsai AK, Khan AY, Worgo CE, et al. A multitkine and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies. Cancer Immunol Res 2017; 5: 790–803.

10. Wu RY, Kong PF, Xia LP, et al. Regorafenib promotes antitumor immunity via inhibiting PD-L1 and IDO1 expression in melanoma. Clin Cancer Res 2019; 25: 4530–4541.

11. Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med 2014; 12: 294.

12. Apolo A, Tomita Y and Lee MJ. Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. J Clin Oncol 2014; 32(Suppl. 15): 4501.

13. Tolaney SM, Ziehr DR, Guo H, et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. Oncologist 2017; 22: 25–32.

14. Patnaik A, Swanson KD, Csizmadia E, et al. Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity. Cancer Discov 2017; 7: 750–765.

15. Tripathi M, Nandana S, Billet S, et al. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget 2017; 8: 87891–87902.

16. Balan M, Mier y Teran E, Waaga-Gasser AM, et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem 2015; 290: 8110–8120.

17. Yau T, Zagonel V, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 2020; 38: 478.

18. Tada Y, Togashi Y, Kotani D, et al. Targeting VEGFR2 with ramucirumab strongly impacts effector/activated regulatory T cells and CD8+ T cells in the tumor microenvironment. J Immunother Cancer 2018; 6: 106.
85. Bang Y-J, Golan T, Lin C-C, et al. Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GJE) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). J Clin Oncol 2019; 37: 2528.

86. Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res 2019; 25: 515–523.

87. Kudo M, Motomura K, Wada Y, et al. First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). J Clin Oncol 2019; 37: 4072.

88. Pickup M, Novitskiy S and Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13: 788–799.

89. Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther 2015; 147: 22–31.

90. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385–7392.

91. Gigantelli G, Fransvea E, Marinosi F, et al. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002; 161: 183–193.

92. Koudelkova P, Costina V, Weber G, et al. Transforming growth factor-beta drives the transendothelial migration of hepatocellular carcinoma cells. Int J Mol Sci 2017; 18: 2119.

93. Huang J, Qiu M, Wan L, et al. TGF-β1 promotes hepatocellular carcinoma invasion and metastasis via ERK pathway-mediated FGFR4 expression. Cell Physiol Biochem 2018; 45: 1690–1699.

94. Li MO and Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008; 134: 392–404.

95. Chen W and Ten Dijke P. Immunoregulation by members of the TGFβ superfamily. Nat Rev Immunol 2016; 16: 723–740.

96. Chen J, Zaidi S, Rao S, et al. Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-beta pathway. Gastroenterology 2018; 154: 195–210.

97. Achyut BR and Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141: 1167–1178.

98. Majumdar A, Curley SA, Wu X, et al. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2012; 9: 530–538.

99. Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol 2018; 19: 222–232.

100. Li H, Han Y, Guo Q, et al. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009; 182: 240–249.

101. Zhang H, Li Z, Wang L, et al. Critical role of myeloid-derived suppressor cells in tumor-induced liver immune suppression through inhibition of NK/T cell function. Front Immunol 2017; 8: 129.

102. Yan W, Liu X, Ma H, et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages. Gut 2015; 64: 1593–1604.

103. de Gramont A, Faivre S and Raymond E. Novel TGF-β inhibitors ready for prime time in onco-immunology. Oncoimmunology 2017; 6: e1257453.

104. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 919–929.

105. Derynck R, Turley SJ and Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. Epub ahead of print 24 July 2020. DOI: 10.1038/s41571-020-0403-1.

106. Dewidar B, Meyer C, Dooley S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells 2019; 8: 1419.

107. Hsieh CC, Hung CH, Lu L, et al. Hepatic immune tolerance induced by hepatic stellate cells. World J Gastroenterol 2015; 21: 11887–11892.

108. Carambia A, Freund B, Schwinge D, et al. TGF-β-dependent induction of CD4+CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells. J Hepatol 2014; 61: 594–599.

109. Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+
110. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–886.

111. Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6: e24671.

112. Prieto J, Melero I and Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015; 12: 681–700.

113. Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology 2014; 59: 1415–1426.

114. Josefowicz SZ, Lu LF and Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30: 531–564.

115. Sharma P and Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56–61.

116. Shen Y, Wei Y, Wang Z, et al. TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem 2015; 35: 1623–1632.

117. Naganuma H, Sasaki A, Satoh E, et al. Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) 1996; 36: 789–795.

118. David CJ and Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol 2018; 19: 419–435.

119. Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGF beta. Nat Rev Immunol 2010; 10: 554–567.

120. Gomes AL, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 2016; 30: 161–175.

121. Martinez GJ, Zhang Z, Reynolds JM, et al. Smad2 positively regulates the generation of Th17 cells. J Biol Chem 2010; 285: 29039–29043.

122. Terabe M and Berzofsky JA. Tissue-specific roles of NKT cells in tumor immunity. Front Immunol 2018; 9: 1838.

123. Morvan MG and Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016; 16: 7–19.

124. Friesen MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated anti-liver cancer immunity. Cancer Res 2018; 78: 3835–3843.

125. Sadallah S, Schmied L, Eken C, et al. Platelet-derived ectosomes reduce NK cell function. J Immunol 2016; 197: 1663–1671.

126. Lazarova M and Steinle A. Impairment of NKG2D-mediated tumor immunity by TGF-β1. Front Immunol 2019; 10: 2689.

127. Trinh TL, Kandell WM, Donatelli SS, et al. Immune evasion by TGFβ1-induced miR-183 repression of MICA/B expression in human lung tumors. Oncoimmunology 2019; 8: e1557372.

128. Sun C, Xu J, Huang Q, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. Oncoimmunology 2017; 6: e1264562.

129. Seeger P, Musso T and Sozzani S. The TGF-β superfamily in dendritic cell biology. Cytokine Growth Factor Rev 2015; 26: 647–657.

130. Mauri C and Menon M. The expanding family of regulatory B cells. Int Immunol 2015; 27: 479–486.

131. Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017; 551: 340–345.

132. Park BV, Freeman ZT, Ghasemzadeh A, et al. TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov 2016; 6: 1366–1381.
135. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682–687.

136. Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017; 169: 1342–1356.e16.

137. Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018; 554: 544–548.

138. Dominguez CX, Müller S, Keerthivasan S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov 2020; 10: 232–253.

139. Colan A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015; 47: 320–329.

140. Dodagatta-Marri E, Meyer DS, Reeves MQ, et al. α-CD-1 therapy elevates Treg/Th balance and increases tumour cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer 2019; 7: 62.

141. Colak S and ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer 2017; 3: 56–71.

142. Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018; 554: 538–543.

143. Vampouille-Box C, Diamond JM, Pilones KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 2015; 75: 2232–2242.

144. Holmgard RB, Schaer DA, Li Y, et al. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer 2018; 6: 47.

145. Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med 2018; 10: eaan5488.

146. David JM, Dominguez C, McCampbell KK, et al. A novel bifunctional anti-PD-L1/TGF-β trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 2017; 6: e1349589.

147. Ravi R, Noonan KA, Pham V, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nat Commun 2018; 9: 741.

148. Wilkins JJ, Vugmeyster Y, Dussault I, et al. Population pharmacokinetic analysis of bintrafusp alfa in different cancer types. Adv Ther 2019; 36: 2414–2433.

149. Doi T, Fujiwara Y, Koyama T, et al. Phase I study of the bifunctional fusion protein bintrafusp alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort. Oncologist 2020; 25: e1292–e1302.

150. Kiss A, Wang NJ, Xie JP, et al. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997; 3: 1059–1066.

151. Boccaccio C and Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006; 6: 637–645.

152. Vejchapidpat P, Tangkijvanich P, Theamboonlers A, et al. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol 2004; 39: 1182–1188.

153. Chen J, Jin R, Zhao J, et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett 2015; 367: 1–11.

154. Xiang Q-F, Zhan M-X, Li Y, et al. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway. Artif Cells Nanomed Biotechnol 2019; 47: 83–89.

155. Yau T, Park J, Finn R, et al. LBA38_PRCheckMate 459: a randomized, multicenter phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019; 30(Suppl. 5): v851–v934.

156. Benkhoucha M, Santiago-Raber ML, Schneider G, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 2010; 107: 6424–6429.
157. Okunishi K, Dohi M, Nakagome K, et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol 2005; 175: 4745–4753.

158. Baek JH, Birchmeier C, Zenke M, et al. The HGF receptor/met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J Immunol 2012; 189: 1699–1707.

159. van der Voort R, Taher TE, Keehnen RM, et al. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. J Exp Med 1997; 185: 2121–2131.

160. Adams DH, Harvath L, Bottaro DP, et al. Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells. Proc Natl Acad Sci U S A 1994; 91: 7144–7148.

161. Kurz SM, Diebold SS, Hieronymus T, et al. The impact of c-met/scatter factor receptor on dendritic cell migration. Eur J Immunol 2002; 32: 1832–1838.

162. Futamatsu H, Suzuki J, Mizuno S, et al. Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ Res 2005; 96: 823–830.

163. Galimi F, Cottone E, Vigna E, et al. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 2001; 166: 1241–1247.

164. Hilkens CM, Kalinski P, de Boer M, et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997; 90: 1920–1926.

165. Rutella S, Bonanno G, Procoli A, et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10+ +IL-12low/neg accessory cells with dendritic-cell features. Blood 2006; 108: 218–227.

166. Fenisguerra V, Di Conza G, Di Matteo M, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015; 522: 349–353.

167. He M, Peng A, Huang XZ, et al. Peritumoral stromal neutrophils are essential for c-Met-elicted metastasis in human hepatocellular carcinoma. Oncoimmunology 2016; 5: e1219828.

168. Kubo Y, Fukushima S, Inamori Y, et al. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. J Dermatol Sci 2019; 93: 33–40.

169. Gloede N, Bald T, van den Boorn-Koninjenberg D, et al. Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy. Immunity 2017; 47: 789–802.e9.

170. Schag K, Schmidt SM, Müller MR, et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 2004; 10: 3658–3666.

171. Kumai T, Matsuda Y, Ohkuri T, et al. c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. Oncoimmunology 2015; 4: e976077.

172. Xing X, Guo J, Ding G, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology 2018; 7: e1356144.

173. Tong G, Cheng B, Li J, et al. MACC1 regulates PD-L1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Cancer Med 2019; 8: 7044–7054.

174. Sim J, Heo YJ, Bae H, et al. MET is overexpressed in microsatellite instability-high gastric carcinoma. Pathol Res Pract 2019; 215: 433–438.

175. Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer 2019; 18: 165.

176. Martin V, Chiriacco C, Modica C, et al. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer 2019; 120: 527–536.

177. Chun H-W and Hong R. Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma. Oncol Lett 2019; 18: 165.

178. Ahn HK, Kim S, Kwon D, et al. MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function. Int J Mol Sci 2019; 20: 4287.

179. Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, et al. MET- oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin Cancer Res 2018; 24: 4579–4587.

180. Li H, Li CW, Li X, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PD-L1. Gastroenterology 2019; 156: 1849–1861.e13.
181. Sun X, Li CW, Wang WJ, et al. Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer Res 2020; 10: 564–571.

182. Hou W, Yuan Q, Yuan X, et al. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Invest New Drugs 2019; 37: 876–889.

183. Sun ZJ, Wu Y, Hou WH, et al. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. Oncotarget 2017; 8: 29067–29079.

184. Lee HJ, Kang HJ, Kim KM, et al. Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma. Clin Mol Hepatol 2015; 21: 60–70.

185. Wu X, Ge H, Lemon B, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem 2010; 285: 5165–5170.

186. Zhao H, Lv F, Liang G, et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation. Oncotarget 2016; 7: 13575–13586.

187. Miura S, Mitsuhashi N, Shimizu H, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 2012; 12: 56.

188. Hyeon J, Ahn S, Lee JJ, et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci 2013; 58: 1916–1922.

189. Chan AW, Zhang Z, Chong CC, et al. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. J Pathol 2019; 249: 166–172.

190. Gao L, Wang X, Tang Y, et al. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res 2017; 36: 8.

191. Gao L, Shen C, Lv F, et al. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Cell Oncol (Dordr) 2018; 41: 85–91.

192. Jones PA and Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–428.

193. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148–1159.

194. Bennett RL and Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol 2018; 58: 187–207.

195. Nelson HH and Kelsey KT. Epigenetic epidemiology as a tool to understand the role of immunity in chronic disease. Epigenomics 2016; 8: 1007–1009.

196. Maio M, Covre A, Fratta E, et al. Molecular pathways: at the crossroads of cancer epigenetics and immunotherapy. Clin Cancer Res 2015; 21: 4040–4047.

197. Chiappinelli KB, Zahnow CA, Ahuja N, et al. Combining epigenetic and immunotherapy to combat cancer. Cancer Res 2016; 76: 1683–1689.

198. Zhang Y, Petroupolos S, Liu J, et al. The signature of liver cancer in immune cells DNA methylation. Clin Epigenetics 2018; 10: 8.

199. Liu J, Liu Y, Meng L, et al. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 2017; 38: 899–907.

200. Sigalotti L, Fratta E, Coral S, et al. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 2014; 142: 339–350.

201. Woods DM, Sodré AL, Villagra A, et al. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res 2015; 3: 1375–1385.

202. Lesterhuis WJ, Punt CJ, Hato SV, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121: 3100–3108.

203. Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015; 527: 249–253.

204. Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2015; 162: 974–986.

205. Héninger E, Krueger TE and Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol 2015; 6: 29.

206. Stone ML, Chiappinelli KB, Li H, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc
207. Patel SA and Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. *Immunity* 2018; 48: 417–433.

208. Liu M, Zhou J, Liu X, *et al*. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. *Gut* 2020; 69: 365–379.

209. Llopiz D, Ruiz M, Villanueva L, *et al*. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor belinostat in a murine hepatocellular carcinoma model. *Cancer Immunol Immunother* 2019; 68: 379–393.

210. Hong YK, Li Y, Pandit H, *et al*. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. *Cell Immunol* 2019; 336: 66–74.

211. Liu M, Zhang L, Li H, *et al*. Integrative epigenetic analysis reveals therapeutic targets to the DNA methyltransferase inhibitor guadecitabine (SGI-110) in hepatocellular carcinoma. *Hepatology* 2018; 68: 1412–1428.

212. Doi T, Muro K, Ishii H, *et al*. A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors. *Clin Cancer Res* 2019; 25: 6614–6622.